FDA
Stories
-
FDA actions, week of October 19, 2026: 5 approvals, 2 proposed rules, 2 notices, 1 announcement
The FDA published 10 actions in the week of October 19 to 25, 2026: 5 approval announcements, 2 proposed rules in the Federal Register, 2 notices in the Federal Register and 1 press announcement.
-
FDA releases guidance on new dietary ingredient notifications
The Food and Drug Administration announced the availability of final guidance titled "New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry." The guidance addresses frequently asked questions and provides recommendations for manufacturers and distributors on the identity and safety information that should be included in an NDIN.
-
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
On October 19, 2026 the FDA granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer that is microsatellite instability high or mismatch repair deficient. The approval was based on AZUR-1, a single-arm trial of 154 patients that reported a 47% sustained clinical complete response at 12 months per independent central review.
-
FDA approves Brytly, a nonprescription eye drop for eye redness
The FDA approved Brytly, apraclonidine ophthalmic solution 0.125%, for relief of eye redness due to minor irritations. The approval is the first nonprescription eye drop containing apraclonidine and is available to adults and children 12 years of age and older.
-
FDA announces support for forward compatibility of eCTD 4.0
The FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research announced support for forward compatibility of Electronic Common Technical Document (eCTD) Version 4.0. This notice informs stakeholders that submissions based on eCTD 4.0 are supported for forward compatibility.
-
FDA authorizes emergency use of four animal drugs for New World screwworm
The FDA issued four Emergency Use Authorizations for products requested by Elanco US Inc., Zoetis Inc., Bimeda Animal Health Ltd., and Sergeant's Pet Care Products LLC to prevent infestations caused by New World screwworm larvae in various animals. The authorizations follow a HHS determination on August 18, 2025 that circumstances justify emergency use.
-
FDA launches Rare Disease Framework Initiative to gather public feedback
The FDA announced the Rare Disease Framework Initiative on October 14, 2026, aiming to create a fit-for-purpose framework for rare disease drug development. It will host an October 28 meeting at its White Oak campus to solicit feedback from patients, advocates, and industry.
-
FDA actions, week of October 12, 2026: 2 approvals, 1 rule, 3 notices, 1 announcement
The FDA published 7 actions in the week of October 12 to 18, 2026: 2 approval announcements, 1 final rule in the Federal Register, 3 notices in the Federal Register and 1 press announcement.
-
FDA approves Hovilpri for immunocompromised adults with unresponsive HSV lesions
The FDA approved Hovilpri (pritelivir) tablets, its page current as of October 9, 2026, for immunocompromised adults whose herpes simplex lesions did not respond to acyclovir, valacyclovir or famciclovir. In a Phase 3 trial, all lesions healed by 28 days in 63% of patients on Hovilpri.
-
FDA finalizes guidance on post-approval manufacturing changes to biosimilars
FDA announced the availability of a final guidance titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." The guidance supersedes the draft issued July 23 2024 and withdraws Q&A I.20 from the Q&A biosimilar development guidance.
-
FDA final rule permits salt substitutes in standardized foods
The rule, effective December 14, 2026, amends FDA's standards of identity to permit the use of salt substitutes in standardized foods. The change is intended to reduce sodium content in these foods.
-
FDA approves Hovilpri for immunocompromised patients with HSV lesions
The FDA approved Hovilpri (pritelivir) tablets for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus and have not responded to acyclovir, valacyclovir, or famciclovir. In a Phase 3 trial, 63% of patients treated with Hovilpri had all lesions healed by 28 days versus 34% with other medications.